I’ve read through the comments, and I hear the collective call for a 'conformist' tone. If strictly sticking to the administrative status quo is what's required for the sake of the board, I’m willing to adjust my frequency, and you know I have. However, let’s be clear: I am fully aware that everything we discuss here is speculation until a PR hits the wire. But there is a difference between 'blind hope' and Informed Inference.
When Pfizer exits ViiV for $1.9 billion, leaving GSK with 78.3% control, they aren't just 'cleaning house.' They are clearing the deck for a modern upgrade to the aging Maraviroc. When the former Head of Global Research Strategy at ViiV, Dr. Max Lataillade, is the one now building our 700mg Mandate, that isn't a coincidence—it’s a clinical blueprint.
Furthermore, Dr. Richard Pestell’s findings on CAMLs proving PD-L1 upregulation in 88% of patients is the exact 'Search Warrant' Big Pharma needs to turn 'Cold' Tumors 'Hot.'
Shionogi’s own S-531011 (anti-CCR8) targets the Treg shields, and pairing it with Leronlimab creates the Molecular Pincer Move the industry has spent billions trying to solve.
In fact, the latest aCCeleR8-001 data from Shionogi reinforces this: their anti-CCR8 achieved a higher ORR response rate specifically in Colorectal Cancer (CRC), which is the exact signal we are tracking in our 700mg trial.
By depleting intratumoral Tregs while Leronlimab unmasks the Tumor and blocks the CCR5 'GPS,' we aren't just speculating; we are describing the only logical 'Triple Threat' for the next generation of oncology.
I’m happy to acknowledge the speculative nature of these posts, but the math doesn't lie. I’ll keep it professional, but I’m staying focused on the May 2026 Scoreboard. Unshaken.
The 2026 Strategic Ledger: Reinforcing the Argument
The recent data from Shionogi’s aCCeleR8-001 trial provides the "clinical glue" for my argument:
ImpactShionogi S-5310116. 5% ORR overall, but significantly higher in CRC. Confirms CRC is the primary target for chemokine-based immune therapy.
Pfizer Exit $1.88B cash-out; GSK takes 78.3% control. Removes the partner conflict, allowing GSK to replace Maraviroc with a monoclonal.
Max Lataillade Architect of ViiV's long-acting pipeline. He is at CytoDyn to ensure Leronlimab fits the GSK/Shionogi ULA (Ultra-Long-Acting) mandate.
Yes, I'm early. Yes, I'll "conform" by cutting my posts here nearly to zero. But the $1.9 billion reality check and the CCR8/CCR5 pincer move explains why Shionogi just upped their stake to 21.7%.
When Pfizer exits ViiV for $1.9 billion, leaving GSK with 78.3% control, they aren't just 'cleaning house.' They are clearing the deck for a modern upgrade to the aging Maraviroc. When the former Head of Global Research Strategy at ViiV, Dr. Max Lataillade, is the one now building our 700mg Mandate, that isn't a coincidence—it’s a clinical blueprint.
Furthermore, Dr. Richard Pestell’s findings on CAMLs proving PD-L1 upregulation in 88% of patients is the exact 'Search Warrant' Big Pharma needs to turn 'Cold' Tumors 'Hot.'
Shionogi’s own S-531011 (anti-CCR8) targets the Treg shields, and pairing it with Leronlimab creates the Molecular Pincer Move the industry has spent billions trying to solve.
In fact, the latest aCCeleR8-001 data from Shionogi reinforces this: their anti-CCR8 achieved a higher ORR response rate specifically in Colorectal Cancer (CRC), which is the exact signal we are tracking in our 700mg trial.
By depleting intratumoral Tregs while Leronlimab unmasks the Tumor and blocks the CCR5 'GPS,' we aren't just speculating; we are describing the only logical 'Triple Threat' for the next generation of oncology.
I’m happy to acknowledge the speculative nature of these posts, but the math doesn't lie. I’ll keep it professional, but I’m staying focused on the May 2026 Scoreboard. Unshaken.
The 2026 Strategic Ledger: Reinforcing the Argument
The recent data from Shionogi’s aCCeleR8-001 trial provides the "clinical glue" for my argument:
ImpactShionogi S-5310116. 5% ORR overall, but significantly higher in CRC. Confirms CRC is the primary target for chemokine-based immune therapy.
Pfizer Exit $1.88B cash-out; GSK takes 78.3% control. Removes the partner conflict, allowing GSK to replace Maraviroc with a monoclonal.
Max Lataillade Architect of ViiV's long-acting pipeline. He is at CytoDyn to ensure Leronlimab fits the GSK/Shionogi ULA (Ultra-Long-Acting) mandate.
Yes, I'm early. Yes, I'll "conform" by cutting my posts here nearly to zero. But the $1.9 billion reality check and the CCR8/CCR5 pincer move explains why Shionogi just upped their stake to 21.7%.
5
